Adult Patients | The Truth About Skin Care

{ Tag Archives } Adult Patients

Theravance And Astellas Announce The Commercial Launch Of VIBATIVTM (telavancin) In The United States

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in the United States. On September 11, 2009, the U.S. Food and Drug Administration (FDA) approved VIBATIV for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus [...]

Also tagged Astellas Pharma Us, Astellas Pharma Us Inc, Fda, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Gram Positive Bacteria, Launch, Mrsa, Nasdaq, September 11, Skin And Skin, Skin Structure Infections, Staphylococcus Aureus, Strains, Telavancin, Theravance Inc, Thrx, United States

2009 11 06 Skin Care News Comments Off

Theravance And Astellas Announce FDA Approval Of VIBATIVTM (telavancin) For The Treatment Of Complicated Skin And Skin Structure Infections

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

Also tagged Astellas Pharma Us, Astellas Pharma Us Inc, Fda, Fda Approval, Fda Approved, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Gram Positive Bacteria, Mrsa, Nasdaq, Skin And Skin, Skin Infections, Skin Structure Infections, Staphylococcus Aureus, Strains, Telavancin, Theravance Inc, Thrx

2009 09 14 Skin Care News Comments Off

FDA Extends Review Timeline For STELARA(TM) (ustekinumab) Biologic License Application By Three Months

Centocor Ortho Biotech Inc. announced that the U.S. Food and Drug Administration (FDA) has extended by three months the review timeline for the Biologic License Application (BLA) for STELARA(TM) (ustekinumab) to provide time for a full review of an amendment to the pending application. The application seeks approval to market STELARA for the treatment of [...]

Also tagged Bla, Fda, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, License Application, Plaque Psoriasis, Psoriasis, Severe Plaque Psoriasis, Systemic Therapy, Three Months, Timeline

2009 05 27 Skin Care News Comments Off

The Truth About Skin Care

{ Tag Archives } Adult Patients

Theravance And Astellas Announce The Commercial Launch Of VIBATIVTM (telavancin) In The United States

Theravance And Astellas Announce FDA Approval Of VIBATIVTM (telavancin) For The Treatment Of Complicated Skin And Skin Structure Infections

FDA Extends Review Timeline For STELARA(TM) (ustekinumab) Biologic License Application By Three Months

Home

Recommendations

Free Ebook

Latest News

Site Features

Get a free ebook valued at $8.95 when you sign up for our free Skincare Tips newsletter. The book The Truth About Skincare: How To Have Younger Looking Skin sells every day for $8.95 at Bargain Books Web. It's yours at no cost by immediate download when you sign up right now. You can unsubscribe any time, and the book is yours to keep.
Name:
Email: